GNCC Capital, Inc. (OTCPK : GNCP) acquired BioCann Pharma S.A.S. for approximately $120 million on February 19, 2019. As part of the consideration, GNCC Capital, Inc. has issued 15 million GNCC Capital, Inc. non-voting shares of Series M Convertible Preferred Stock at $1 per share and a total amount of 3.5 billion RESTRICTED GNCC Capital, Inc. shares of common stock at $0.0003 per share. The consideration being issued is dependent upon BioCann achieving net revenues of not less than $12 million in the period commencing on April 1, 2019 to the period March 31, 2020. The purchase price shall be paid within 5 business days from the effective date being February 19, 2019. R Y Lowenthal and N E Blom to remain as directors until the close of the transition period, being March 31, 2019. BioCann will appoint one director to GNCC Board shortly and to nominate directors to replace R Y Lowenthal and N E Blom on March 31, 2019. Agreement strictly prohibits any reverse split of the GNCC shares of Common Stock for a period of not less than 18 months. The transaction is subject to approval by acquirer board and approval by the shareholders. The transaction was approved by shareholders voting in excess of 51% of the outstanding shares of voting Common Stock. As of February 19, 2019, the acquirer board also approved the transaction. GNCC Capital, Inc. (OTCPK : GNCP) acquired BioCann Pharma S.A.S. on February 19, 2019.